menu
    • menu
    [{"orgOrder":0,"company":"GALENA BIOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2011","type":"Inapplicable","leadProduct":"Nelipepimut-S","moa":"ERBB2","graph1":"Oncology","graph2":"Phase III","graph3":"GALENA BIOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"GALENA BIOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"GALENA BIOPHARMA \/ Undisclosed"},{"orgOrder":0,"company":"GALENA BIOPHARMA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Anagrelide Hydrochloride","moa":"Phosphodiesterase 3","graph1":"Hematology","graph2":"Phase II","graph3":"GALENA BIOPHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GALENA BIOPHARMA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GALENA BIOPHARMA \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by GALENA BIOPHARMA

    Menu

    GALENA BIOPHARMA

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            GALENA BIOPHARMA

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            GALENA BIOPHARMA

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anagrelide Hydrochloride

                            Therapeutic Area : Hematology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow D...

                            Details : Anagrelide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thrombocytosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 29, 2014

                            Lead Product(s) : Anagrelide Hydrochloride

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            GALENA BIOPHARMA

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            GALENA BIOPHARMA

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of NeuVaxâ„¢ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence

                            Details : NeuVax vaccine (Nelipepimut-S) is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Breast Neoplasms.

                            Product Name : NeuVax vaccine

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 24, 2011

                            Lead Product(s) : Nelipepimut-S

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth